Brightgene Bio-medical Technology Co (SHSE:688166) Ending Cash Position: ¥1,312 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688166 Brightgene Bio-medical Technology Co Ltd SHSE:688166
85 GF Score
Price ¥36.00
GF Value ¥42.35
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Brightgene Bio-medical Technology Co Ending Cash Position?

Brightgene Bio-medical Technology Co SHSE:688166 -2.07% 85 Ending Cash Position is ¥1,312 Mil as of Jun. 2026. GuruFocus rates SHSE:688166 with a GF Score™ of 85/100 and a GF Value™ of ¥42.35 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Brightgene Bio-medical Technology Co's Ending Cash Position for the quarter that ended in Jun. 2026 was ¥1,312 Mil.

Brightgene Bio-medical Technology Co's quarterly Ending Cash Position increased from Dec. 2025 (¥955 Mil) to Mar. 2026 (¥1,357 Mil) but then declined from Mar. 2026 (¥1,357 Mil) to Jun. 2026 (¥1,312 Mil).

Brightgene Bio-medical Technology Co's annual Ending Cash Position declined from Dec. 2023 (¥971 Mil) to Dec. 2024 (¥754 Mil) but then increased from Dec. 2024 (¥754 Mil) to Dec. 2025 (¥955 Mil).

Brightgene Bio-medical Technology Co Ending Cash Position Related Terms

Brightgene Bio-medical Technology Co Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Brightgene Bio-medical Technology Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brightgene Bio-medical Technology Co Ending Cash Position Chart

Brightgene Bio-medical Technology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 333.22 1,151.74 971.04 754.10 955.06

Brightgene Bio-medical Technology Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 730.83 600.22 955.06 1,357.40 1,312.32
SHSE:688166
85GF Score
Brightgene Bio-medical Technology Co Ltd SHSE:688166
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brightgene Bio-medical Technology Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Brightgene Bio-medical Technology Co's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=754.102+200.961
=955

Brightgene Bio-medical Technology Co's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1386.908+-74.588
=1,312

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of ¥1,312 Mil mean?
Brightgene Bio-medical Technology Co (SHSE:688166) has a Ending Cash Position of ¥1,312 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Brightgene Bio-medical Technology Co and its competitors.
Is Brightgene Bio-medical Technology Co's Ending Cash Position too high?
Brightgene Bio-medical Technology Co's current Ending Cash Position is ¥1,312 Mil. Overall, Brightgene Bio-medical Technology Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Brightgene Bio-medical Technology Co's Ending Cash Position compare to VRTX and REGN?
Brightgene Bio-medical Technology Co's Ending Cash Position of ¥1,312 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Brightgene Bio-medical Technology Co and its competitors. Brightgene Bio-medical Technology Co's current Ending Cash Position is ¥1,312 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brightgene Bio-medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co (SHSE:688166) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥42.35, compared to a current price of ¥36.00 — trading 15% below its estimated fair value. The current Ending Cash Position is ¥1,312 Mil. Brightgene Bio-medical Technology Co's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Brightgene Bio-medical Technology Co (SHSE:688166), the current Ending Cash Position is ¥1,312 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Brightgene Bio-medical Technology Co (SHSE:688166) Overvalued in 2026?

Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co stock appears to be undervalued. The current stock price of ¥36.00 is trading 15% below its estimated GF Value™ of ¥42.35. GuruFocus considers Brightgene Bio-medical Technology Co to be Modestly Undervalued.

Key valuation signals for SHSE:688166:

  • Ending Cash Position: ¥1,312 Mil
  • GF Value™: ¥42.35 vs. price of ¥36.00 (15% below fair value)
  • GF Score™: 85/100 with 6 warning signs

No single metric tells the full story. See the SHSE:688166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Brightgene Bio-medical Technology Co Business Description

Address No. 218 Xinghu Street, Buildings C25-C28, Nanotechnology Park, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215123
Brightgene Bio-medical Technology Co Ltd is engaged in the Research and development and production of pharmaceutical intermediates, active pharmaceutical ingredients and formulations with high technological barriers.
85GF Score

Get the complete analysis for SHSE:688166

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥36.00
Price
¥42.35
GF Value